Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917275 | 1.00 | CYP1A2 (0.38) | CYP1A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL17148636 | 0.98 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4729067 | 0.92 | CHRNB2 (0.34) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13698049 | 0.92 | CHRNB2 (0.34) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13698050 | 0.92 | CHRNB2 (0.34) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL9891493 | 0.81 | — | — | |
| SCHEMBL24003182 | 0.81 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL8161674 | 0.81 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL22267858 | 0.81 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL15314566 | 0.81 | CYP1A2 (0.35) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | CYP1A2 3174/4885CHRNB2 4876/4885CHRNA7 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.